2nd Quarter - Report

FRESENIUS MEDICAL CARE NORTH AMERICA for FRESENIUS MEDICAL CARE NORTH AMERICA

Firm
Client
Income
—
Expenses
$1,350,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

The Restore Protections for Dialysis Patients Act (No Bill Number yet) Labor cost issues related to the ESRD Bundle base rate in the PPS proposed rule Transitional Drug Add-on Payment Adjustment (TDAPA) Dialysis preparedness planning Chronic Kidney Disease Improvement in Research and Treatment Act (no bill number) Calendar Year (CY) 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Forecast Error Adjustment Framework (Letter from House and Senate to CMS) H.R.2853 - Expanding Care in the Home Act (House) Medicare secondary payer issues

Foreign entity interest: Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America) and has an interest in the issues lobbied.

LobbyistCovered position, as disclosed
LAURA KEMPER —
CAMERON LYNCH —
TALEEN MEKHDJAVAKIAN —
COURTNEY SIMMONE VEATCH —

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2853 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.